Our pipeline

With an unmatched understanding of the mechanisms of hearing disorders in neurodegeneration and inflammation, CILcare has developed a proprietary pipeline of compounds. CILcare’s excellence led to the selection of a derisked & robust pipeline.

CILcare’s assets are currently in preclinical phases. The main goal is to develop targeted therapies to treat the early signs of age-related hearing disorders and to delay the onset of neurodegenerative and inflammatory diseases.